A biotech startup let an agent choose a gene therapy and successfully inject the treatment, offering a startling glimpse of the future of research labs.

In breathless press releases and posts, the company has touted its models’ ability to deliver scientific breakthroughs. But its IPO filing taps the brakes on just how fast its AI will lead to big discoveries.

It’s the latest in a growing wave of bets that AI companies are making on brain data.

OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.

The DNA inside our cells isn’t just a series of instructions, but something far more dynamic. Like scientists, AI models don't yet have the data to properly decode it.

In her new book on biological warfare, Annie Jacobsen didn’t even discuss AI because scientists can already warp Mother Nature to create extinction-level events.

“The experiments are still in the queue. The PR is already live,” says one expert.

Of all the threats presented by uncontrollable artificial intelligence, scientists say death by plague ranks low.